Pulmatrix, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. on December 15, 2021. The filing details the entry into a Material Definitive Agreement for a registered direct offering and the proposal of a reverse stock split to maintain compliance with NASDAQ listing standards.
Key Financial Metrics and Transaction Details
The filing does not provide historical revenue, profit, cash flow, or margin data. The primary financial event is a capital raise structured as follows:
- Gross Proceeds: Approximately $6.75 million.
- Securities Issued: 6,745.0008 shares of Series A Convertible Preferred Stock (stated value $1,000/share) and 5,620,834 Common Warrants.
- Conversion Terms: Preferred Stock converts to Common Stock at an initial price of $0.60 per share, resulting in an aggregate of 11,241,668 shares.
- Warrant Terms: Common Warrants have an exercise price of $0.70 per share, exercisable after six months, expiring five years later.
- Placement Agent Fees: 7.0% cash fee on gross proceeds, plus a 1.0% management fee, $25,000 for expenses, and $50,000 for legal fees. The agent also received warrants to purchase up to 730,708 shares at $0.75 per share.
- Use of Proceeds: General corporate and working capital purposes.
Material Changes and Corporate Actions
The filing announces a proposed Reverse Stock Split with a ratio between 1-for-2 and 1-for-20. This action requires shareholder approval via a special meeting. The Preferred Stock issued in the offering will automatically convert upon the effectuation of the Reverse Stock Split. The Preferred Stock holders have agreed to vote in favor of the Reverse Stock Split proposal.
Outlook, Risks, and Contingencies
The offering is expected to close on or about December 17, 2021, subject to customary closing conditions. Key contingencies include:
- Shareholder approval for the amendment to the Certificate of Incorporation to effect the Reverse Stock Split.
- Shareholder approval to increase authorized Common Stock shares.
- Beneficial ownership limitations: Holders cannot convert or exercise warrants if it would cause them to own more than 4.99% (or 9.99% upon election) of outstanding Common Stock.
Management commentary is limited to the intent to use proceeds for working capital and the necessity of the reverse split. No specific operational risks or guidance regarding future product milestones are detailed in this specific filing.
Investor Verification Checklist
- Verify the final ratio of the Reverse Stock Split once approved by shareholders.
- Confirm the closing date of the offering and the actual net proceeds received after fees.
- Review the upcoming Proxy Statement for details on the Reverse Stock Split and voting procedures.
- Monitor the conversion of Preferred Stock into Common Stock post-approval.
- Check for any changes in the company's cash position in subsequent quarterly filings (10-Q/10-K).